1. Targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: effectiveness and value : final evidence report Publication: Boston, MA : Institute for Clinical and Economic Review, December 2 2016 Subject(s): Comparative Effectiveness ResearchImmunologic Factors -- therapeutic usePsoriasis -- drug therapyAdalimumab -- therapeutic useBenchmarkingEtanercept -- therapeutic useImmunologic Factors -- adverse effectsImmunologic Factors -- economicsInterleukin-12 -- antagonists & inhibitorsInterleukin-17Interleukin-23 -- antagonists & inhibitorsPhosphodiesterase 4 InhibitorsPhototherapyPsoriasis -- immunologyPsoriasis -- therapyRandomized Controlled Trials as TopicSeverity of Illness IndexTumor Necrosis Factor-alpha -- antagonists & inhibitorsUstekinumab -- therapeutic useValue-Based PurchasingHumansUnited States
